Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Amortization of Deferred Charges (2019 - 2021)

aTYR PHARMA (ATYR) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $212000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Amortization of Deferred Charges rose 79.66% year-over-year to $212000.0, compared with a TTM value of $829000.0 through Dec 2021, up 18.94%, and an annual FY2021 reading of $829000.0, up 18.94% over the prior year.
  • Amortization of Deferred Charges was $212000.0 for Q4 2021 at aTYR PHARMA, up from $206000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $235000.0 in Q2 2021 and bottomed at $118000.0 in Q4 2020.
  • Average Amortization of Deferred Charges over 3 years is $188083.3, with a median of $191000.0 recorded in 2019.
  • The sharpest move saw Amortization of Deferred Charges plummeted 39.49% in 2020, then surged 79.66% in 2021.
  • Year by year, Amortization of Deferred Charges stood at $195000.0 in 2019, then tumbled by 39.49% to $118000.0 in 2020, then soared by 79.66% to $212000.0 in 2021.
  • Business Quant data shows Amortization of Deferred Charges for ATYR at $212000.0 in Q4 2021, $206000.0 in Q3 2021, and $235000.0 in Q2 2021.